This company has been acquired
ASXC Stock Overview
A medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Asensus Surgical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.35 |
| 52 Week High | US$0.40 |
| 52 Week Low | US$0.17 |
| Beta | 1.38 |
| 1 Month Change | 2.66% |
| 3 Month Change | 44.36% |
| 1 Year Change | 23.54% |
| 3 Year Change | -84.04% |
| 5 Year Change | -97.12% |
| Change since IPO | -98.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| ASXC | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 21.9% | 2.8% | 3.9% |
| 1Y | 23.5% | 11.0% | 11.6% |
Return vs Industry: ASXC exceeded the US Medical Equipment industry which returned 12.7% over the past year.
Return vs Market: ASXC underperformed the US Market which returned 25.3% over the past year.
Price Volatility
| ASXC volatility | |
|---|---|
| ASXC Average Weekly Movement | 13.4% |
| Medical Equipment Industry Average Movement | 9.6% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: ASXC's share price has been volatile over the past 3 months.
Volatility Over Time: ASXC's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 208 | Anthony Fernando | www.asensus.com |
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company’s products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue.
Asensus Surgical, Inc. Fundamentals Summary
| ASXC fundamental statistics | |
|---|---|
| Market cap | US$94.92m |
| Earnings (TTM) | -US$83.80m |
| Revenue (TTM) | US$9.85m |
9.6x
P/S Ratio-1.1x
P/E RatioIs ASXC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASXC income statement (TTM) | |
|---|---|
| Revenue | US$9.85m |
| Cost of Revenue | US$12.85m |
| Gross Profit | -US$3.00m |
| Other Expenses | US$80.80m |
| Earnings | -US$83.80m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.31 |
| Gross Margin | -30.45% |
| Net Profit Margin | -850.75% |
| Debt/Equity Ratio | 0% |
How did ASXC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/08/22 07:47 |
| End of Day Share Price | 2024/08/22 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Asensus Surgical, Inc. is covered by 12 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Chodaczek | B. Riley Securities, Inc. |
| Sean Lavin | BTIG |
| Ross Osborn | Cantor Fitzgerald & Co. |